Arbutus Biopharma (ABUS)

• Market cap: $836M
• 1 day: 1.87%
• 5 days: -1.13%
• 1 month: -2.9%
• 3 months: 34.57%
• 6 months: 30.54%
• Year to date: 32.52%
• 1 year: 7.65%
• 5 years: 54.06%
• 10 years: -27.45%
• Sector: Healthcare
• Industry: Biotechnology

About: Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Employees: 44